C19061501-F
- Generic Name
- C19061501-F
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
- Conditions
- Amyotrophic Lateral Sclerosis (Healthy Volunteers)
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT05797701
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
- Conditions
- Amyotrophic Lateral SclerosisHealthy Volunteer
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT05797753
- Locations
- 🇺🇸
Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
- Conditions
- Amyotrophic Lateral Sclerosis (Healthy Volunteers)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT05795907
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 174
- Registration Number
- NCT05630547
- Locations
- 🇧🇪
Investigational Site Number : 0560001, Bruxelles, Belgium
🇧🇬Investigational Site Number : 1000002, Sofia, Bulgaria
🇨🇦Investigational Site Number : 1240002, Ottawa, Ontario, Canada
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 305
- Registration Number
- NCT05237284
- Locations
- 🇺🇸
University of Pennsylvania Site Number : 8400021, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital Site Number : 8400014, Philadelphia, Pennsylvania, United States
🇨🇦Investigational Site Number : 1240008, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.